News Search Results
Mar 24, 2025, 10:30 ET Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics
[email protected] (973) 723-7832 About Regor Therapeutics GroupRegor Therapeutics Group is a clinical-stage biotechnology company, headquartered in Cambridge, MA and with operations in Houston, TX,
More news about: Sermonix Pharmaceuticals; Regor Therapeutics Group
Mar 24, 2025, 08:12 ET Abu Dhabi Gears Up to Host 25,000 Global Participants at AIM Congress in April
diverse sectors, including intelligent agriculture, energy, infrastructure, finance & stock exchange, ICT, manufacturing, medical tourism, biotechnology, medical technology, pharmaceuticals, international trade, logistics & transportation, water technology, tourism, and education. The
More news about: AIM Congress
Mar 24, 2025, 08:00 ET Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued
More news about: Anixa Biosciences, Inc.
Mar 24, 2025, 08:00 ET SineuGene Therapeutics Announces FDA IND Clearance for SNUG01, a First-in-Class TRIM72-Targeted Gene Therapy for ALS
populations. About SineuGene SineuGene Therapeutics Co., Ltd., often referred to as "SineuGene," is a biotechnology company focused on developing innovative therapies for neurological diseases. Established in late 2021, the company builds on over a decade of scientific
More news about: SineuGene Therapeutics
Mar 24, 2025, 07:59 ET Abu Dhabi Gears Up to Host 25,000 Global Participants at AIM Congress in April
diverse sectors, including intelligent agriculture, energy, infrastructure, finance & stock exchange, ICT, manufacturing, medical tourism, biotechnology, medical technology, pharmaceuticals, international trade, logistics & transportation, water technology, tourism, and education. The
More news about: AIM Congress
Mar 24, 2025, 05:45 ET ICLR LAWSUIT ALERT: The Gross Law Firm Notifies ICON Public Limited Company Investors of a Class Action Lawsuit and Upcoming Deadline
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Gross Law Firm
Mar 23, 2025, 19:56 ET Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced IND clearance
More news about: Clover Biopharma
Mar 21, 2025, 13:50 ET Cardiac Biomarkers Market to be Worth $10.08 Billion by 2031--Exclusive Report by Meticulous Research®
North America held the largest share of the market, primarily driven by significant R&D investments by pharmaceutical and biotechnology companies, the rising prevalence of cardiovascular diseases, a well-established healthcare infrastructure, government support for biomarker research
More news about: Meticulous Market Research Pvt. Ltd.
Mar 21, 2025, 12:40 ET Genmab, NHS England, Pistoia Alliance and Regeneron Win Bio-IT World Innovative Practices Awards
Manufacturing and Process Development: an Industry 4.0 digitalization platform for real-time automated decision-making": "Like others in the biotechnology space, [Regeneron Pharmaceuticals faces] the challenges of orchestrating the systems, applications, and integrations that power [their] laboratory
More news about: Bio-IT World Conference & Expo
Mar 21, 2025, 12:00 ET ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (3) that the RFPs ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Mar 21, 2025, 10:45 ET TCBP Announces Transition from Nasdaq to OTC Markets
March 21, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on March
More news about: TC BioPharm
Mar 21, 2025, 09:00 ET Aphranel® MagiCCrystal CaHA Filler from Shanghai MOYOM Biotec, Obtains NMPA Class III Medical Device Certificate in China
other countries. Global Expansion: Innovation-Academia-Research Ecosystem As a National high-tech enterprise, Shanghai Moyom Biotechnology has built an innovation network through a "Chinese R&D + Local transformation" model: Research Collaboration: Partnering with
More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD
Mar 21, 2025, 08:47 ET ICLR Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against ICON Public Limited Company (ICLR)
insufficient to shield the company from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 21, 2025, 07:30 ET Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Mar 21, 2025, 07:10 ET Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Bio's other assets, including ongoing trials of tobevibart (a broadly neutralizing monoclonal antibody targeting HBV) run by Vir Biotechnology, Inc. ("Vir Biotechnology," Nasdaq: VIR). Upcoming 2025 data readouts from these studies will guide Brii Bio's late-stage development
More news about: Brii Biosciences Limited
Mar 21, 2025, 07:10 ET 騰盛博藥發佈2024年度全年財務業績及公司最新進展
中ENSURE研究治療結束時（EOT）數據顯示，靶向HBV的小干擾核糖核酸（siRNA）藥物elebsiran對取得更高HBV功能性治癒率起到直接作用。目前elebsiran正在進行多項臨床試驗，評估其與騰盛博藥的其他資產的聯用，包括Vir Biotechnology, Inc. （ 「Vir Biotechnology」，納斯達克股票代碼：VIR）正在對 tobevibart（一種針對HBV的廣譜中和單克隆抗體）開展的試驗。這些研究即將在2025年公佈的數據，將為公司的後期開發及註冊策略帶來指引。騰盛博藥仍有3.357億美元的充足現金儲備，足以支持公司完成乙肝功能性治癒後期開發計劃。
More news about: 騰盛博藥生物科技有限公司
Mar 21, 2025, 07:00 ET The Galien Foundation Honors 2025 Modi Prix Galien India Award Recipients
PuneProf. Sudhan Shuvrati, Founder Dean of the Translational Health Science and Technology Institute regional Centre for Biotechnology, Professor at the Regional Centre for Biotechnology (RCB)Fellow of the Indian National Science Academy (INSA), the National Academy of Sciences, India
More news about: The Galien Foundation
Mar 21, 2025, 06:53 ET Nanomi Receives CMO Award for Life Science Leadership in Drug Delivery
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Mar 21, 2025, 06:52 ET Nanomi Receives CMO Award for Life Science Leadership in Drug Delivery
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Mar 21, 2025, 05:45 ET Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 11, 2025 in ICON Lawsuit - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Levi & Korsinsky, LLP
Mar 21, 2025, 04:21 ET Friends Afar: How do Chinese scientists grow soybeans in Pakistan?
the familiar terrain of his homeland. "Agriculture is food for poor countries," he says. Rehman's journey led him to the fields of biotechnology, where he grappled with the intricacies of herbicide resistance and genetically modified wheat. In 2016, while pursuing his doctorate at Chonnam
More news about: chinadailyhk.com
Mar 20, 2025, 18:00 ET Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
reach out to your respective H.C. Wainwright representative. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Mar 20, 2025, 17:56 ET Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update
March 20, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Mar 20, 2025, 17:32 ET Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today
More news about: Eupraxia Pharmaceuticals Inc.
Mar 20, 2025, 17:31 ET DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight
stage products, and the key multiple myeloma companies, including CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical
More news about: DelveInsight Business Research, LLP